COMPANY PROFILE

mbiomics

Explore full profile

Casting light on the microbiome

Munich, GermanyFounded 2020Biotech & Life Sciences

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About mbiomics

mbiomics is a Munich techbio company developing scalable microbiome-based therapeutics for severe and chronic diseases. Its platform designs defined microbial consortia informed by proprietary fluorescence microscopy profiling, with lead candidate MBX-116 advancing as an immune checkpoint inhibitor co-therapy for second-line advanced melanoma (Phase 1B planned for 2027) and a broader pipeline toward autoimmune and neurodegenerative indications. After a €13 million Series A first close in March 2023 led by MIG Capital with HTGF, Bayern Kapital and private seed investors, mbiomics announced a €12 million third closing in April 2026 that brought the total Series A to €30 million, with existing investors including MIG Fonds and Bayern Kapital participating; proceeds fund IND-enabling pharmacology, GMP manufacturing and clinical preparation. Sources: mbiomics / GlobeNewswire 28 Apr 2026; BioSpace (2023 first close).

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Munich, Germany
Employees: 43
Open positions: 1
Dealroom signal: 88.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Microbiome, Hard Tech, Woman Founder, DT and LS, start2 group, German Accelerator, science-based
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Apr 2026	$13M	$72M	Bayern Kapital · MIG Capital	↗
EARLY VC✓Equity / VC	Apr 2025	$0	—	Bayern Kapital	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

mbiomics website traffic

Latest recorded traffic for mbiomics is 810 monthly website visits, up 211.5% over the last three months. mbiomics's team grew 19.4% over the past year.

Latest monthly visits810 3-month web change+211.5% 1-year team growth+19.4%

Monthly website visitsMar 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

(Senior) Director Data ScienceMünchen, Bavaria, Germany · Data Science & Engineering · Jul 10, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OHOrbit HealthHarnessing sensors and AI, enables effective early intervention and personalized care for chronic diseases	Berlin, Germany	Operational	11	$1.5M	—
ANAnvajoA Dresden-based technology company that develops, manufactures and sells innovative solutions for the analysis of liquids	Dresden, Germany	Operational
BTBreath TherapeuticsPursuing groundbreaking therapies by unleashing the true potential of inhaled drug delivery	Munich, Germany	Acquired
CSCellbox SolutionsLive cell logistics solutions for research, development and shipment of life-sustaining therapies	Norderstedt, Germany	Operational
BRBreakthroughHelping people to improve their lives by providing them with access to information and resources that can help them to reach their goals	Berlin, Germany	Operational
PRProvolutA powerful AI-based app for protein design, delivering superior outcomes with fewer lab experiments, and handling multiple targets for properties	Berlin, Germany	Operational
MOmo:reDevelops the micro-lab, a user-friendly platform that allows researchers to automate, standardise and digitise advanced 3D cell culture experiments	Berlin, Germany	Operational
PTPROSION TherapeuticsPROSION Therapeutics is a drug development company with a proprietary platform that addresses highly unmet medical needs by unlocking undruggables	Cologne, Germany	Operational